PMID

Data

Article Title

Organization

II. Discovery of a novel series of CXCR3 antagonists with a beta amino acid core.

Sanofi

I. Discovery of a novel series of CXCR3 antagonists. Multiparametric optimization of N,N-disubstituted benzylamines.

Sanofi

N-Arylsulfonyl-a-amino carboxamides are potent and selective inhibitors of the chemokine receptor CCR10 that show efficacy in the murine DNFB model of contact hypersensitivity.

Boehringer Ingelheim Pharmaceuticals

Discovery and Characterization of Biased Allosteric Agonists of the Chemokine Receptor CXCR3.

Friedrich-Alexander University

IV. Discovery of CXCR3 antagonists substituted with heterocycles as amide surrogates: improved PK, hERG and metabolic profiles.

Merck Research Laboratories

Exploring a pocket for polycycloaliphatic groups in the CXCR3 receptor with the aid of a modular synthetic strategy.

Vu University Amsterdam

CXCR3 antagonists: quaternary ammonium salts equipped with biphenyl- and polycycloaliphatic-anchors.

Vu University Amsterdam

Chemical subtleties in small-molecule modulation of peptide receptor function: the case of CXCR3 biaryl-type ligands.

Vu University Amsterdam

Chemokine receptor antagonists.

National Heart And Lung Institute

Lead identification of 2-iminobenzimidazole antagonists of the chemokine receptor CXCR3.

Abbott Bioresearch Center

Development of CXCR3 antagonists. Part 4: discovery of 2-amino-(4-tropinyl)quinolines.

Ucb Pharma

Discovery of small molecule benzimidazole antagonists of the chemokine receptor CXCR3.

Abbott Bioresearch Center

Design and optimization of imidazole derivatives as potent CXCR3 antagonists.

Amgen

Discovery and optimization of a series of quinazolinone-derived antagonists of CXCR3.

Amgen

Discovery of potent and specific CXCR3 antagonists.

Amgen

III. Identification of novel CXCR3 chemokine receptor antagonists with a pyrazinyl-piperazinyl-piperidine scaffold.

Merck Research Laboratories

Special ergolines efficiently inhibit the chemokine receptor CXCR3 in blood.

Novartis Institutes For Biomedical Research

II. SAR studies of pyridyl-piperazinyl-piperidine derivatives as CXCR3 chemokine antagonists.

Ligand Pharmaceuticals

Discovery of a novel series of CXCR3 antagonists.

Merck Serono

Optimization of a series of quinazolinone-derived antagonists of CXCR3.

Amgen

Identification of a new class of small molecule C5a receptor antagonists.

Wyeth Research

Novel CXCR3 antagonists with a piperazinyl-piperidine core.

Ligand Pharmaceuticals

Imidazo-pyrazine derivatives as potent CXCR3 antagonists.

Amgen

Special ergolines are highly selective, potent antagonists of the chemokine receptor CXCR3: discovery, characterization and preliminary SAR of a promising lead.

Novartis Institutes For Biomedical Research

Synthesis and structure-activity relationship of benzetimide derivatives as human CXCR3 antagonists.

Johnson & Johnson Prd

Camphor sulfonamide derivatives as novel, potent and selective CXCR3 antagonists.

Glaxosmithkline

Optimization of the heterocyclic core of the quinazolinone-derived CXCR3 antagonists.

Amgen

Development of CXCR3 antagonists. Part 3: Tropenyl and homotropenyl-piperidine urea derivatives.

Ucb Pharma

Development of CXCR3 antagonists. Part 2: Identification of 2-amino(4-piperidinyl)azoles as potent CXCR3 antagonists.

Ucb Pharma

Identification and structure-activity relationships of 1-aryl-3-piperidin-4-yl-urea derivatives as CXCR3 receptor antagonists.

Ucb Pharma

Identification and initial evaluation of 4-N-aryl-[1,4]diazepane ureas as potent CXCR3 antagonists.

Pharmacopeia Drug Discovery

Synthesis and structure-activity relationship of 3-phenyl-3H-quinazolin-4-one derivatives as CXCR3 chemokine receptor antagonists.

Vrije Universiteit Amsterdam

Quantitative evaluation of each catalytic subsite of cathepsin B for inhibitory activity based on inhibitory activity-binding mode relationship of epoxysuccinyl inhibitors by X-ray crystal structure analyses of complexes.

Osaka University Of Pharmaceutical Sciences

Synthesis and structure-activity relationships of 7-substituted 3-(2, 6-dichlorophenyl)-1,6-naphthyridin-2(1H)-ones as selective inhibitors of pp60(c-src).

University Of Auckland